Supplementary Data — Sotrovimab reduced COVID-19 risk: real-time meta analysis of 28 studies

@CovidAnalysis, November 2025, Version 48V48
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COMET-ICE Gupta (DB RCT) 80% 0.20 [0.01-4.16] death 0/528 2/529 Improvement, RR [CI] Treatment Control COMET-ICE Gupta (DB RCT) 89% 0.11 [0.01-2.06] ventilation 0/528 4/529 COMET-ICE Gupta (DB RCT) 75% 0.25 [0.11-0.57] progression 7/528 28/529 COMET-ICE Gupta (DB RCT) 79% 0.21 [0.09-0.50] death/hosp. 6/528 30/529 Ong 61% 0.39 [0.05-2.90] death 1/19 10/75 Ong 56% 0.44 [0.11-1.73] ICU 2/19 18/75 Ong 59% 0.41 [0.17-0.99] progression 19 (n) 75 (n) Aggarwal (PSM) 89% 0.11 [0.00-0.79] death 0/522 15/1,563 Aggarwal (PSM) 62% 0.38 [0.20-0.67] hosp. 11/522 89/1,563 Aggarwal (PSM) -11% 1.11 [0.78-1.53] progression 44/522 119/1,563 Zaqout -165% 2.65 [0.60-11.3] progression 4/345 3/583 Gleeson 66% 0.34 [0.01-8.04] death 0/47 1/48 Gleeson 80% 0.20 [0.01-4.09] death 0/47 2/48 Gleeson 66% 0.34 [0.01-8.04] ICU 0/47 1/48 Gleeson 90% 0.10 [0.01-0.77] hosp. 1/47 10/48 Aggarwal 38% 0.62 [0.07-2.77] death 1/1,542 7/3,663 Aggarwal 18% 0.82 [0.56-1.18] hosp. 39/1,542 116/3,663 Aggarwal -3% 1.03 [0.80-1.29] progression 93/1,542 224/3,663 Piccicacco 66% 0.34 [0.01-8.13] death 0/88 1/90 Piccicacco 35% 0.65 [0.26-1.60] hosp. 7/88 11/90 Piccicacco 66% 0.34 [0.14-0.76] hosp./ER 7/88 21/90 Piccicacco 90% 0.10 [0.01-0.78] progression 1/88 10/90 Kneidinger -20% 1.20 [0.64-2.27] severe case 21/125 13/93 Suzuki -8% 1.08 [0.69-1.70] progression 672 (n) 1,257 (n) Brown -258% 3.58 [0.73-17.5] hosp. 6/186 2/222 Zheng 50% 0.50 [0.31-0.81] death/hosp. 34/3,331 61/2,689 OT​1​ Zheng 46% 0.54 [0.33-0.88] death/hosp. 32/3,331 55/2,689 OT​1​ Zheng (PSW) 4% 0.96 [0.52-1.79] death/hosp. 2,847 (n) 4,836 (n) OT​1​ Zheng (PSW) -14% 1.14 [0.58-2.22] death/hosp. 19/2,847 33/4,836 OT​1​ Evans 27% 0.73 [0.55-0.98] death/hosp. 1,079 (n) 4,973 (n) Goodwin 75% 0.25 [0.01-5.17] death 0/169 2/336 Goodwin 60% 0.40 [0.09-1.79] hosp. 2/169 10/336 Goodwin -21% 1.21 [0.59-2.51] hosp. 11/169 18/336 Kip 30% 0.70 [0.43-1.12] death/hosp. 22/500 63/999 Tazare 16% 0.84 [0.75-0.93] death/hosp. Miyashita 60% 0.40 [0.08-2.06] ventilation 2/844 5/844 Miyashita 33% 0.67 [0.11-3.98] ventilation 2/642 3/642 Miyashita 80% 0.20 [0.01-4.14] ventilation 0/202 2/202 Miyashita 55% 0.45 [0.30-0.66] oxygen 34/844 76/844 Miyashita 54% 0.46 [0.30-0.73] oxygen 26/642 56/642 Miyashita 60% 0.40 [0.18-0.89] oxygen 8/202 20/202 Drysdale (PSW) 29% 0.71 [0.16-3.20] death 599 (n) 5,191 (n) Drysdale (PSW) 50% 0.50 [0.24-1.06] death/hosp. 599 (n) 5,191 (n) Drysdale (PSW) 57% 0.43 [0.18-1.00] hosp. 599 (n) 5,191 (n) De Vito 81% 0.19 [0.07-0.47] death 18/341 63/348 De Vito 92% 0.08 [0.03-0.17] oxygen 17/341 144/348 Behzad 74% 0.26 [0.11-0.59] death/ICU 569 (n) 611 (n) Bell (PSW) 24% 0.76 [0.66-0.88] death/hosp. population-based cohort Bell (PSW) 21% 0.79 [0.68-0.90] hosp. population-based cohort Farmer (PSM) -20% 1.20 [0.91-1.58] death/hosp. 1,603 (n) 6,299 (n) Bell (PSM) 50% 0.50 [0.19-1.33] death 5/854 20/1,708 Bell (PSM) 12% 0.88 [0.53-1.45] death/hosp. 21/854 48/1,708 Bell (PSM) 74% 0.26 [0.09-0.73] ICU 4/854 31/1,708 Bell (PSM) 59% 0.41 [0.28-0.60] oxygen 30/854 148/1,708 Bell (PSM) -20% 1.20 [0.67-2.14] hosp. 18/854 30/1,708 Maria (PSW) 72% 0.28 [0.04-1.42] death 39 (n) 42 (n) Maria (PSW) 77% 0.23 [0.05-0.83] progression 39 (n) 42 (n) Drysdale 4% 0.96 [0.94-0.99] PASC population-based cohort Drysdale 8% 0.92 [0.89-0.96] PASC 9,504 (n) 9,523 (n) ACTIV-3/TICO Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 ACTIV-3/TICO Self (DB RCT) 11% 0.89 [0.73-1.10] no recov. 22/182 27/178 ACTIV-3/TICO Self (DB RCT) 7% 0.93 [0.63-1.35] no recov. 181 (n) 178 (n) Woo (PSM) -140% 2.40 [0.78-7.41] death 4/60 10/360 Woo (PSM) -50% 1.50 [0.98-2.29] death 36/87 24/87 RECOVERY Horby (RCT) 6% 0.94 [0.80-1.11] death 263/828 300/895 RECOVERY Horby (RCT) 5% 0.95 [0.77-1.16] death 177/828 201/895 RECOVERY Horby (RCT) 25% 0.75 [0.56-0.99] death 82/355 106/365 RECOVERY Horby (RCT) -4% 1.04 [0.93-1.18] no disch. 828 (n) 895 (n) RECOVERY Horby (RCT) 2% 0.98 [0.84-1.16] death/ICU 184/799 201/863 Sotrovimab COVID-19 outcomes c19early.org November 2025 ​1​ OT: comparison with other treatment Favors sotrovimab Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.